Posted by Michael Wonder on 12 Dec 2019
BioCryst submits new drug application for oral, once daily berotralstat (BCX7353) to prevent HAE attacks
11 December 2019 - BioCryst Pharmaceuticals announced it has submitted a new drug application to the U.S. FDA for approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks.
“Hereditary angioedema patients are waiting for a safe, effective oral therapy to manage their disease and this submission brings berotralstat an important step closer to meeting this need for patients and their physicians,” said Jon Stonehouse, chief executive officer of BioCryst.
